AGITG 2013* , ,
Presentations this author is a contributor to:
First-line cetuximab with FOLFOX or FOLFIRI every 2 weeks in KRAS wild-type metastatic colorectal cancer: phase II APEC study (#17)
12:45 PM
Timothy Price
Poster Review